- Contract Awards
Emergent BioSolutions (NYSE: EBS) has received a potential 10-year, $535M contract to supply the Department of Health and Human Services with intravenous medications designed to treat patients experiencing adverse events following smallpox vaccination. The company said Monday it will provide Vaccinia Immune Globulin Intravenous products that HHS...


